Directly-acting agents (DAA) against HCV have impressively improved treatment of chronic hepatitis C coinfection. However, relapses still occur. Therefore we assessed the influence of traditional risk factors on treatment outcome in HCV/HIV coinfected patients in the German hepatitis C cohort (GECCO).
The GECCO cohort is a multicenter cohort from 9 sites in Germany. All HCV/HIV coinfected patients (361/1791) with complete follow-up having received one of the following DAA regimen were analysed: Pegylated interferon plus ribavirin (RBV) + sofosbuvir (SOF); SOF + RBV; SOF + simeprevir; SOF + daclatasvir +/- RBV; SOF + ledipasvir; paritaprevir/ritonavir, ombitasvir +/- RBV and +/- dasabuvir. Treatment outcome was measured as sustained virologic response 12 weeks after end of therapy (SVR12). Fisher’s exact, chi-square and Mann-Whitney U test were used for statistical analysis.
319/361 (88%) patients were male, median age was 48 years (IQR:42-53). HCV genotype (GT) distribution was: GT1 69%, GT2 3%, GT3 10%, GT4 18%. 65/170 (38%) had IL28B C/C polymorphism. 103/361 (29%) had high baseline HCV RNA (>6 Mio IU/mL). Median baseline ALT was 66U/l (44-109). 172/361 (48%) were treatment-experienced (TE). Liver cirrhosis was present in 71/361 (20%). Median CD4 nadir was 218/ul (129-374). 62/361 (17%) had baseline CD4 <350/ul, 54/361 (15%) baseline CD4 <20%. 357/361 (99%) were on cART. 78/361 (22%) were on opiate substitution therapy (OST). Overall SVR rate was 94%. In univariate analysis neither sex (p=0.588), age (p=0.439), GT (p=0.615), high HCV RNA (p=0.749), ALT (p=0.901), DAA regimen (p=0.390), TE (p=0.479), CD4 nadir (p=0.473) or OST (p=0.267) were statistically significantly associated with SVR. However, patients with CD4 <350/ul (p=0.038), CD4 <20% (p=0.017) and with liver cirrhosis (p=0.003) were less likely to achieve SVR (see figure 1). In multivariate analysis only liver cirrhosis (p=0.02, OR 3.5 (95%CI 1.2-9.9)) remained statistically significantly associated with Non-SVR.
Despite considerably improved efficacy of treatment of chronic hepatitis C with DAAs in HCV/HIV-coinfection liver cirrhosis remains as a risk factor for DAA treatment failure. Low CD4 cells were highly correlated with liver cirrhosis probably due to splenomegaly causing lymphopenia. This highlights the need for early initiation of DAA therapy in HCV/HIV coinfection before the onset of higher liver fibrosis/cirrhosis to allow for optimal rates of viral eradication.